

## Protective effect of bifidobacteria in an experimental model of *Clostridium difficile* associated colitis

Fernando M. Trejo<sup>1</sup>, Graciela L. De Antoni<sup>2,3</sup> and Pablo F. Pérez<sup>1,2\*</sup>

<sup>1</sup>CCT La Plata – CONICET – Centro de Investigación y Desarrollo en Criotecología de Alimentos (CIDCA), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, 47 y 116, La Plata 1900, Argentina

<sup>2</sup>Cátedra de Microbiología, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, 47 y 116, La Plata 1900, Argentina

<sup>3</sup>CIC-PBA-Comisión de Investigaciones Científicas de la Provincia de Buenos Aires, Argentina

Received 17 February 2012; accepted for publication 17 January 2013; first published online 23 April 2013

The aim of this study was to evaluate the ability of *Bifidobacterium* strains to prevent the effects associated with *Clostridium difficile* infection in a hamster model of enterocolitis. After clindamycin treatment (30 mg/kg), animals were infected intragastrically with *C. difficile* ( $5 \times 10^8$  CFU per animal). Seven days prior to antibiotic administration, probiotic treatment was started by administering bacterial suspensions of bifidobacteria in drinking water. Strains CIDCA 531, CIDCA 5310, CIDCA 5316, CIDCA 5320, CIDCA 5323 and CIDCA 5325 were used. Treatment was continued during all the experimental period. Development of diarrhoea, enterocolitis and mortality were evaluated. All the infected animals belonging to the placebo group developed enterocolitis (5/5) and only two dead (2/5) whereas in the group administered with *Bifidobacterium bifidum* strain CIDCA 5310 the ratio of animals with enterocolitis or dead decreased significantly (1/5 and 0/5 respectively). Biological activity of caecum contents was evaluated in vitro on Vero cells. Animals treated with strain CIDCA 5310 presented lower biological activity than those belonging to the placebo group. The present study shows the potential of selected strains of bifidobacteria to antagonise, in vivo, the virulence of *C. difficile*.

**Keywords:** *Bifidobacterium*, *Clostridium difficile*, hamster model, enterocolitis, probiotics.

*Clostridium difficile* is a Gram (+) spore forming bacteria, inhabiting the intestinal tract of several animal species, e.g. pigs, calves, dogs, horses, cats and mice (Arroyo et al. 2005; Songer & Anderson, 2006; Avberse et al. 2009). In piglets, *C. difficile* has been associated with neonatal enteritis (Hopman et al. 2011). In humans, *C. difficile* is an important cause of nosocomial diarrhoea, mainly antibiotic associated diarrhoea.

The microorganism is carried asymptotically in about 50% of neonates, 20% of hospitalised patients and 2% of healthy adults (Matsuki et al. 2005; Gursoy et al. 2007). In hospitalised individuals, proton pump inhibitors or antibiotics such as clindamycin, cephalosporins, fluoroquinolones and ampicillin can cause imbalance of the normal intestinal microbiota thus leading to overgrowth of intestinal *C. difficile*, or colonisation by environmental microorganisms that are normally present in health care centres

(Schroeder, 2005; Sunenshine & McDonald, 2006). *C. difficile* is responsible for 90–100% of cases of pseudo-membranous colitis (PMC), 60–75% of antibiotic-associated colitis and 30–60% of antibiotic-associated diarrhoea (AAD) (Limaye et al. 2000).

The main virulence factors of this microorganism are two large protein toxins: TcdA (308 kDa) and TcdB (260 kDa). These toxins act as glycosyltransferases on small GTPases that are involved in actin polymerisation and cytoskeleton assembly (Jank et al. 2007). In the hamster model, TcdB but not TcdA, is an essential virulence factor in *C. difficile* infection (Lyras et al. 2009). Some *C. difficile* strains produce a third toxin named binary toxin (CDT) (Popoff et al. 1988) an AB type toxin constituted by two components: CdtA (48 kDa) and CdtB (75 kDa). CdtB (receptor-binding component) form a heptamer onto cellular surface, allowing for the internalisation and enzymatic activity (ADP-ribosyl transferase) of CdtA (Barth et al. 2004). These events trigger cytoskeleton disorganisation, cell death and nutrient release into the extracellular milieu (Schwan et al. 2009). Although relevance of CDT during pathogenic process of *C. difficile*

\*For correspondence; e-mail: pfp@biol.unlp.edu.ar

infection has not been so far confirmed, this factor seems to be associated with higher severity in the infections (McDonald et al. 2005).

Recommended therapy for *C. difficile*-associated diarrhoeas involves the use of antibiotics such as metronidazole for mild-moderate illness and high doses of vancomycin for severe illness (Cohen et al. 2010). Several studies suggest that probiotics could constitute an alternative approach for the prophylaxis and/or treatment of *C. difficile* associated diarrhoea (CDAD). In this context, there are reports showing the correction of microbiota imbalances by administration of probiotics (Wullt et al. 2003; Plummer et al. 2004; Segarra-Newnham, 2007) or prebiotics (Lewis et al. 2005).

We have demonstrated that growth and adhesion of the pathogen onto Caco-2 cells are significantly reduced by extracellular factors present in spent culture supernatants of bifidobacteria (Trejo et al. 2006). In addition, co-culture of *C. difficile* with selected strains of bifidobacteria leads to a dramatic reduction of the biological activity of supernatants due to clostridial toxins (Trejo et al. 2010). These findings are very interesting because bifidobacteria colonise the same intestinal region as *C. difficile* and they are included in the formulation of many dairy products thus allowing for the prevention/treatment of the infection by nutritional intervention.

Taking into account above-mentioned results we assessed the effect of administration of bifidobacteria on the course of an experimental infection with *C. difficile* in a hamster model.

## Materials and methods

### Preparation of bacterial suspensions

*C. difficile* strain 117 is a clinical isolate obtained from the Servicio de Bacteriología, Hospital Muñiz, Buenos Aires, Argentina. This strain was characterised in our laboratory as belonging to TcdA+/TcdB+ toxinotype (Trejo et al. 2010). Clostridia were inoculated in BHI (Biokar, Diagnostics-Zac de Ther) supplemented with 0.05% w/v cysteine (Laboratorios ANEDRA, Argentina; BHI-Cys) and incubated anaerobically (AnaeroPak, Mitsubishi Gas Chemical Co, Inc) at 37 °C for 20 h. Fifty ml of bacterial culture were centrifuged at 12 000 g for 10 min. Bacteria were washed twice with sterile phosphate saline buffer (PBS: 0.144 g KH<sub>2</sub>PO<sub>4</sub>/l, 9 g NaCl/l, 0.795 g Na<sub>2</sub>HPO<sub>4</sub>/l, pH 7.5) and suspended in 4 ml sterile PBS. Bacterial concentration was evaluated in a haemocytometer and adjusted to 10<sup>9</sup> bacteria/ml in PBS.

Six bifidobacterial strains (Table 1) were selected according to their ability to antagonise growth, adhesion to enterocytes in culture and biological activity of spent culture supernatants of *C. difficile* (Trejo et al. 2006; Trejo et al. 2010). *Bifidobacterium* strains were grown in MRS broth (DIFCO, Becton Dickinson and Company Sparks, MD 21252, USA) supplemented with 0.05% w/v cysteine (MRS-cys) at 37 °C for 24 h in anaerobic conditions

**Table 1.** *Bifidobacterium* sp. strains

| Bifidobacterium species     | Strains    |
|-----------------------------|------------|
| <i>Bifido. bifidum</i>      | CIDCA 5310 |
| <i>Bifido. longum</i>       | CIDCA 5316 |
| <i>Bifido. longum</i>       | CIDCA 5320 |
| <i>Bifido. longum</i>       | CIDCA 5325 |
| <i>Bifido. longum</i>       | CIDCA 5323 |
| <i>Bifido. pseudolongum</i> | CIDCA 531  |

Strain CIDCA 531 was isolated from a fermented milk product. Remaining *Bifidobacterium* strains were isolated from infant faeces (age between 6 d and 4 months), breastfed (Gomez Zavaglia et al. 1998; Pérez et al. 1998)

(AnaeroPak, Mitsubishi Gas Chemical Co, Inc). Bacterial suspensions were obtained from 1 l of *Bifidobacterium* culture. Afterwards, cultures were centrifuged at 12 000 g for 10 min, washed twice with sterile PBS and bacteria were suspended in sterile PBS and stored at –80 °C until use. Counts were performed by plating serial dilutions of the cultures on MRS-cys/agar 1.5% (w/v). Plates were incubated at 37 °C for 72 h in anaerobic conditions (AnaeroPak, Mitsubishi Gas Chemical Co, Inc).

### Infection protocol and probiotic administration


Specific pathogen free female Golden Syrian hamsters of 45–60 days old (100–150 g) were used (Instituto de Biología y Medicina Experimental, CONICET, Argentina). Animals were housed in polypropylene cages covered with polyester filters (4 or 5 animals per cage). Food, water, bedding, cages, wire lids and filter covers were sterilised (15 min, 121 °C) before use. Food and water were administered *ad libitum* throughout.

The time line and general schedule of the experiments are depicted in Fig. 1. Animals were allocated to 3 experimental groups:

- IC (infected controls)
- IPT (infected probiotic treated)
- UC (uninfected controls)

Animals of the IPT group (Infected Probiotic-Treated) were administered daily with suspensions of bifidobacteria in drinking water at concentration of 2 × 10<sup>8</sup> CFU/ml. Probiotic administration started at day 0 and was continued until the end of the experiment. Fresh bacteria suspensions were given daily in order to administer high doses of viable microorganisms (around 1 × 10<sup>9</sup> CFU per animal per day). Infected controls (IC) and uninfected controls (UC) received drinking water throughout. The UC group was included in order to assess the effectiveness of the infection confinement measures.

On day 7 animals belonging to all experimental groups were intragastrically (i.g.) administered 100 µl clindamycin (Parafarm, Drogueria Saporiti, Argentina) solution (30 mg/ml in PBS) at dose 30 mg/kg/animal. In hamsters, clindamycin treatment results in microbiota imbalance predisposing



**Fig. 1.** Time line of the study. Administration of bifidobacterial suspensions ( $1 \times 10^9$  per animal per day) begins at day 0 and continues until the end of the experiment. Clindamycin was administered at a single dose ( $100 \mu\text{l}$  of a  $30 \text{ mg/ml}$  solution in PBS per animal).

animals to *C. difficile* infection (Chang et al. 1978). Four days later (day 11) animals of the IC and IPT groups received intragastrically *C. difficile* strain 117 ( $5 \times 10^8$  bacteria/animal). Uninfected controls (UC) received PBS instead of *C. difficile*. At day 4 post-infection (day 15), surviving animals were euthanized by  $\text{CO}_2$  inhalation and cervical dislocation.

Two independent experiments were conducted: (1) Strain selection and kinetics: Six bifidobacterial strains. Groups IC ( $n=5$ ); IPT ( $n=5$ ) and UC ( $n=4$ ) and (2) Strain CIDCA 5310: Groups IC and IPT ( $n=8$  each).

All the procedures were performed according to international and local regulations related to animal welfare.

#### Infection markers

Animals were observed daily and mortality, morbidity and presence of diarrhoea were recorded. Criteria used to evaluate moribund animals were auto isolation, lethargy, skin erosions and stooped posture. Animals judged to be in a moribund state were euthanized as described above.

#### Biological activity of caecal content

After sacrifice, 1 g caecal content was collected and homogenised with 1 ml PBS. The suspension was centrifuged at  $12\,000 \text{ g}$  for 10 min and supernatants were filter sterilised ( $0.45 \mu\text{m}$ ). Filtrates were stored at  $-80^\circ\text{C}$  until use.

Biological activity was assessed as previously described (Trejo et al. 2010). Briefly, Vero cells, grown in 48 well plates for 48 h, were treated for 16 h ( $37^\circ\text{C}$ , 5%  $\text{CO}_2$  – 95% air atmosphere) with 2 fold serial dilutions of filtrates in DMEM. Detached cells were removed by washing with PBS. Remaining cells were fixed with 2% (v/v) formaldehyde and stained with crystal violet solution (0.13% w/v crystal violet; 5% v/v ethanol; 2% v/v formaldehyde in PBS).

Next, an extraction with 50% (v/v) ethanol was performed and  $\text{OD}_{540}$  was determined. Biological activity was

expressed as the ratio of detached cells (rd), according to the following expression:

$$\text{rd} = 100 * (1 - (\text{ODs} - \text{OD0}) / (\text{ODc} - \text{OD0}))$$

where:

ODs: optical density of sample.

OD0: optical density of well without cells (control of stain adsorption by the well).

ODc: optical density of untreated control cells

By using this equation, filtrate concentration leading to 50% of cell detachment was calculated (DD50). This value inversely correlates with the biological activity of the filtrates. To confirm that biological activity was associated with TcdB the assay was repeated in the presence of monoclonal antibody anti-TcdB ( $10 \mu\text{l}$  per  $100 \mu\text{l}$  filtrate, Meridian Life Science, Inc., CA, USA). Biological activity was abrogated in the presence of anti-TcdB antibody.

#### Histological studies

Samples of caeca were removed, fixed by using 5% (v/v) paraformaldehyde and embedded in paraffin. Sections ( $5 \mu\text{m}$ ) were hydrated and stained with haematoxylin/eosin.


#### Statistical analysis

Results were analysed by log-rank (Mantel-Cox) survival analysis, non-parametric test (Mann-Whitney) or Fisher's exact test (two-tailed) using GraphPad Prism version 5.00 for Windows, (GraphPad Software, San Diego California USA).

## Results

#### Effect of *C. difficile* infection

Hamsters, administered with clindamycin and subsequently challenged with *C. difficile* strain 117 showed evident signs of infection at day 15 (4 d post infection).



**Fig. 2.** Effect of *C. difficile* infection in hamster. (a) animal administered with *B. bifidum* CIDCA 5310 ( $2 \times 10^8$  CFU/animal) and infected with *C. difficile* ( $5 \times 10^8$  CFU/animal). (b) Infected control.

Indeed inflammation of caecum and colon, increased intestinal gas, viscous yellowish caecal content and tissue fragility were observed. These signs are evident in Fig. 2b that clearly contrasts with Fig. 2 A corresponding to an uninfected control. Above-mentioned findings were considered as markers of colitis. Diarrhoea was evidenced by wet tail and presence of faecal halo in the perianal region.

#### Probiotic strain selection

As shown in Table 2, infection of hamsters belonging to the IC group (infected controls) with strain 117 of *C. difficile* lead to diarrhoea in 4/5 animals, enterocolitis in 5/5 animals and 2/5 animals died before the final time point (4 d after infection). Interestingly, preventive administration of strain CIDCA 5310 significantly ( $P=0.02$ ) reduced the ratio of animals with enterocolitis (1/5) as compared with the IC group group (5/5). An independent experiment conducted with strain CIDCA 5310 (not shown in Table 2) showed ratios of enterocolitis of 2/8 and 7/8 for the treatment and placebo group respectively. This represent a significant difference between the two groups ( $P=0.02$ ).

Other strains under study, did not lead to a significant protective effect although strains CIDCA 5323 and CIDCA 5325 showed 2 out of 5 animals with enterocolitis thus leading to a trend ( $P=0.08$ ) of protective effect. In the uninfected control group, neither enterocolitis or diarrhoea were observed and no deaths occurred. This indicates appropriate confinement of infection.

#### Effect of *Bifido bifidum* CIDCA 5310 on the kinetics of *C. difficile* associated diarrhoea

Kinetics of development of enterocolitis was significantly different when placebo and probiotic-treated groups were compared. As shown in Fig. 3, no mortality and only 1 hamster showing signs of diarrhoea were found in the IPT group at day 4 post-infection. In contrast, in the IC group diarrhoea and death were evident at days 1 and 2 post-

infection respectively. At the end of experimentation period, 2/5 animals died and 5/5 showed signs of diarrhoea in IC group.

#### Histology

As shown in Fig. 4, caeca of animals belonging to the IC group show evidence of cellular infiltration with enlarged sub-mucosal region (Fig. 4 B1), typical volcanic eruption lesion (Fig. 4 B2) and oedema (Fig. 4 B3). In contrast, normal appearance was demonstrated in histological sections of CIDCA 5310-treated infected animals (Fig. 4 C1, C2 and C3). Histological characteristics of this group were similar to those of uninfected controls (Fig. 4 A1, A2 and A3). Intestinal epithelium breakdown produced during *C. difficile* pathology allows passage of polymorphonuclear cells from sub-mucosa through luminal area (Fig. 4b). Viscous aspect of intestinal content, shown in Fig. 2b, normally is associated with fibrin effusion that gives rise to the characteristic volcanic eruption lesion found in histological analysis (Waters et al. 1998).

#### Biological activity of caecal content

As depicted in Fig. 5, biological activity of filtrates of caecal content revealed significant differences between groups. Indeed, samples from the placebo group had lower DD50 (higher biological activity) than those belonging to the 5310-treated group ( $P=0.016$ ). Non-biological activity associated to TcdB was evidenced in non-infected control group (data not shown).

#### Discussion

Treatment of *C. difficile* associated diarrhoea (CDAD), generally performed with metronidazole or vancomycin has proved to have an effectiveness of 95% (Kelly et al. 1994). However, there is evidence of increasing failure of this conventional therapy (Aslam et al. 2005) as well as relapse ratios ranging from 20 to 50% (Musher et al. 2005; Pepin et al. 2005).


Since CDAD is associated with disruption of the intestinal microbiota, strategies encompassing administration of probiotic microorganisms constitute a promising approach. These nutritional interventions have been addressed in human trials that revealed the suitability of probiotics to improve the course of this pathology (reviewed in Gougoulias et al. 2007).

*C. difficile* can lead to severe infectious diarrhoea in pigs (Songer & Anderson, 2006) but the most suitable animal model to mimics human infection is the Syrian Golden hamster (*Mesocricetus auratus*) (Chang et al. 1978). It has been reported that administration of nontoxigenic strains of *C. difficile* 3 d before challenge with toxigenic strains prevented colonisation of hamster (Sambol et al. 2002). This protective effect has been correlated with decrease in colonisation by clostridia.

**Table 2.** Ratios of animals with diarrhoea, enterocolitis or dead. Animals received clindamycin (30 mg/kg) at day 7 and they were infected with  $5 \times 10^8$  CFU/animal *C. difficile* strain 117 at day 11. Results were recorded 4 d after infection. Control animals received antibiotic treatment but they were no infected nor probiotic-treated

| Treatment           | Experimental group | Ratio     |               |       |
|---------------------|--------------------|-----------|---------------|-------|
|                     |                    | Diarrhoea | Enterocolitis | Death |
| CIDCA531            | IPT                | 5/5       | 3/5           | 0/5   |
| CIDCA5310           |                    | 1/5       | 1/5(*)        | 0/5   |
| CIDCA5316           |                    | 4/5       | 4/5           | 2/5   |
| CIDCA5320           |                    | 4/5       | 4/5           | 1/5   |
| CIDCA5323           |                    | 3/5       | 2/5           | 3/5   |
| CIDCA5325           |                    | 3/5       | 2/5           | 0/5   |
| Infected controls   | IC                 | 4/5       | 5/5           | 2/5   |
| Uninfected controls | UC                 | 0/4       | 0/4           | 0/4   |

(\*) Significantly difference from placebo group (Fisher's exact test,  $P < 0.05$ )



**Fig. 3.** Enterocolitis and death in hamsters infected with *C. difficile* strain 117 ( $5 \times 10^8$  CFU/animal). Infected Probiotic-Treated (IPT) animals were administered with  $2 \times 10^8$  CFU/ml of *B. bifidum* CIDCA 5310 in drinking water starting at day 0 until end of experiment.

Treatment with *Saccharomyces boulardii* reduces mortality of hamsters infected with *C. difficile* (Toothaker & Elmer, 1984). Even though in vitro studies have shown that *Sac. boulardii* is able to inactivate *C. difficile* toxins by proteolytic cleavage (Castagliuolo et al. 1996; Buts, 2008) this effect has not been demonstrated in vivo.

In the present study, we show for the first time the protective effect of a selected strain of *Bifido bifidum* (CIDCA 5310) in a hamster model of CDAD. Continuous administration of strain CIDCA 5310 in drinking water starting 11 d before infection with *C. difficile*, leads to a significant amelioration of symptoms and increased survival ratio in the probiotic-treated group. Protective effect was observed at least for 4 d post infection.


Even though six bifidobacterial strains were tested, only strain CIDCA 5310 was able to antagonise the effect of

*C. difficile*. Interestingly, other strains (Trejo et al. 2006) showed higher in vitro inhibitory potential than strain CIDCA 5310 (e.g. CIDCA 5320 ad CIDCA 5323) and also higher capability to antagonise adhesion to cultured human enterocytes (e.g. strains CIDCA 5316, 5320, 5323 and 5325). Although none of these characteristics were found in strain CIDCA 5310, co-culture of this strain with toxinogenic *C. difficile* dramatically reduces biological activity of spent culture supernatants as compared with pure clostridial cultures (Trejo et al. 2010). Furthermore, it has been demonstrated that culture of *C. difficile* in the presence of strain CIDCA 5310 leads to lower concentrations of TcdA and TcdB in the spent culture supernatants. These findings have been ascribed to either decrease of toxin release or synthesis diminution with no inhibition of *C. difficile* growth (Trejo et al. 2010). Interestingly, in the present study we detected lower biological activity in faecal samples of probiotic-treated animals as compared with the control group.


In agreement with the above mentioned findings animals administered with strain CIDCA 5310 showed better general condition, lower ratio of enterocolitis and lower mortality compared with placebo-treated group.

It is worth noting that the protective effect of strain CIDCA 5310 was found even in a model that includes antibiotic administration. Indeed, in the present study hamsters were administered with clindamycin at day 7 to facilitate infection by *C. difficile*. It has been demonstrated (Larson & Borriello, 1990) that this antibiotic remains in the caecal content at potentially inhibitory concentrations (4–6  $\mu\text{g/g}$ ) for up to 11 d. These concentrations are higher than minimal inhibitory concentrations (MIC) reported by Xiao et al. (2010) but daily administration of bifidobacteria from day 0 until the end of the study provides daily intake of living microorganisms.

The effect of strain CIDCA 5310 could be related to several factors that involve balance of the intestinal microbiota and immunomodulation. However, the ability of strain CIDCA 5310 to decrease in vivo, the biological activity of faecal contents seems to be a finding of particular relevance given



**Fig. 4.** Histology of caecum stained with Haematoxylin-Eosin. (A1, A2, A3): uninfected control (UC). (B1, B2, B3) infected control (IC). (C1, C2, C3) *B. bifidum* CIDCA 5310-treated infected animal (IPT) e: oedema, sm: sub-mucosa, lp: lamina propria, i: cellular infiltrate, L: lumen, ve: volcanic eruption.



**Fig. 5.** Biological activity of faecal filtrates from hamsters belonging to the IPT or IC groups. Animals of the IPT group were administered with strain CIDCA 5310. Results are expressed as mean of DD50/gr of faecal sample  $\pm$  SD. \*Significant difference by Mann-Whitney test ( $P=0.0159$ ).

the main role of secreted TcdA and TcdB in the course of the pathology. Noteworthy, the low proteolytic activity of bifidobacteria precludes degradation of toxins in the gut as a mechanism for explaining the protective effect.

Results reported in the present study emphasise the importance of strain selection for improving the likelihood of successful interventions. Even though the mechanisms have not been elucidated, results presented here encourage further research on the use of bifidobacteria-containing products in the prophylaxis/treatment of CDAD.

This work was supported by the Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Comisión de Investigaciones Científicas de la Provincia de Buenos Aires (CIC-PBA) and Universidad Nacional de La Plata (UNLP). Authors are indebted to R. Rollet from the Servicio de Bacteriología of the Hospital Muñiz (Buenos Aires, Argentina) for kindly provide strain 117 of *C. difficile*.

## References

- Arroyo LG, Kruth SA, Willey BM, Staempfli HR, Low DE & Weese JS 2005 PCR ribotyping of *Clostridium difficile* isolates originating from human and animal sources. *Journal of Medical Microbiology* **54** 163–166
- Aslam S, Hamill RJ & Musher DM 2005 Treatment of *Clostridium difficile*-associated disease: old therapies and new strategies. *Lancet Infectious Disease* **5** 549–557
- Avberse J, Janezic S, Patee M, Rupnik M, Zidaric M, Logar K, Vengust M, Zemljic M, Pirs T & Ocepek M 2009 Diversity of *Clostridium difficile* in pigs and other animals in Slovenia. *Anaerobe* **15** 252–255
- Barth H, Aktories K, Popoff MR & Stiles BG 2004 Binary bacterial toxins: biochemistry, biology and applications of common *Clostridium*

- and Bacillus proteins. *Microbiology and Molecular Biology Reviews* **68** 373–402
- Buts JP** 2008 Twenty-five years of research on *Saccharomyces boulardii* trophic effects: updates and perspectives. *Digestive Disease Science* **54** 15–18
- Castagliuolo I, LaMont JT, Nikulasson ST & Pothoulakis C** 1999 *Saccharomyces boulardii* protease inhibits *Clostridium difficile* toxin A effects in the rat ileum. *Infection and Immunity* **64** 5225–5232
- Chang TW, Bartlett LG, Gorbach SL & Onderdonk AB** 1978 Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. *Infection and Immunity* **20** 526–529
- Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J & Wilcox MH** 2010 Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). *Infection Control and Hospital Epidemiology* **31** 431–455
- Gomez Zavaglia A, Kociubinski G, Pérez PF & De Antoni GL** 1998 Isolation and characterization of *Bifidobacterium* strains for probiotic formulation. *Journal of Food Protection* **61** 865–873
- Gougoulis C, Tuohy KM & Gibson GR** 2007 Dietary-based gut flora modulation against *Clostridium difficile* onset. *Food Science and Technology Bulletin: Functional Foods* **4** 31–41
- Cursoy S, Guven T, Arıkan K, Yurci A, Torun E, Baskol EM, Ozbakir O & Yucesoy M** 2007 *Clostridium difficile* infection frequency in patients with nosocomial infections or using antibiotics. *Hepatogastroenterology* **54** 1720–1724
- Hopman NE, Keessen EC, Harmanus C, Sanders IM, van Leengoed LA, Kuijper EJ & Lipman LJ** 2011 Acquisition of *Clostridium difficile* by piglets. *Veterinary Microbiology* **149** 186–192
- Jank T, Giesemann T & Aktories K** 2007 Rho-glucosylating *Clostridium difficile* toxins A and B: new insights into structure and function. *Glycobiology* **17** 15R–22R
- Kelly CP, Pothoulakis C & LaMont JT** 1994 *Clostridium difficile* colitis. *New England Journal of Medicine* **330** 257–262
- Larson HE & Borriello SP** 1990 Quantitative study of antibiotic-induced susceptibility to *Clostridium difficile* enterocytitis in hamsters. *Antimicrobials Agents and Chemotherapy* **34** 1348–1353
- Lewis S, Burmeister S & Brazier J** 2005 Effect of the probiotic oligofructose on relapse of *Clostridium difficile*-associated diarrhea: a randomized, controlled study. *Clinical Gastroenterology and Hepatology* **3** 442–448
- Limaye AP, Turgeon DK, Cookson BT & Fritsche TR** 2000 Pseudomembranous colitis caused by a toxin A(–) B(+) strain of *Clostridium difficile*. *Journal of Clinical Microbiology* **38** 1696–1697
- Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, Gerding DM & Rood JI** 2009 Toxin B is essential for virulence of *Clostridium difficile*. *Nature* **458** 1176–1179
- Matsuki S, Ozaki E, Shozu M, Inoue M, Shimizu S, Yamaguchi N, Karasawa T, Yamagishi T & Nakamura S** 2005 Colonization by *Clostridium difficile* of neonates in a hospital and infants and children in three day-care facilities of Kanazawa, Japan. *International Microbiology* **8** 43–48
- McDonald LC, Killgore GE, Thompson A, Owens RC, Kazakova VC, Sambol SP, Johnson S, & Gerding DN** 2005 An epidemic, toxin gene-variant strain of *Clostridium difficile*. *New England Journal of Medicine* **353** 2433–2441
- Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F & Hamill RJ** 2005 Relatively poor outcome after treatment of *Clostridium difficile* colitis with metronidazole. *Clinical Infectious Diseases* **40** 1586–1590
- Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, Godin D & Bourassa C** 2005 Increasing risk of relapse after treatment of *Clostridium difficile* colitis in Quebec, Canada. *Clinical Infectious Diseases* **40** 1591–1597
- Pérez PF, Minnaard J, Disalvo EA & De Antoni GL** 1998 Surface properties of bifidobacterial strains of human origin. *Applied Environmental Microbiology* **64** 21–26
- Plummer S, Weaver MA, Harris JC, Dee P & Hunter J** 2004 *Clostridium difficile* pilot study: effects of probiotic supplementation on the incidence of *C. difficile* diarrhoea. *International Microbiology* **7** 59–62
- Popoff MR, Rubin EJ, Gill DM & Boquet P** 1988 Actin-specific ADP-ribosyltransferase produced by a *Clostridium difficile* strain. *Infection and Immunity* **56** 2299–2306
- Sambol SP, Merrigan MM, Tang JK, Johnson S & Gerding DN** 2002 Colonization for the prevention of *Clostridium difficile* disease in hamsters. *Journal of Infectious Diseases* **186** 1781–1789
- Schroeder M** 2005 *Clostridium difficile* associated diarrhea. *American Family Physician* **71** 921–928
- Schwan C, Stecher B, Tzivelekidis T, van Ham V, Rohde M, Hardt WD, Wehland J & Aktories K** 2009 *Clostridium difficile* toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. *PLoS Pathogens* **5** e10000626. doi: 10.1371/journal.ppat.1000626
- Segarra-Newnham M** 2007 Probiotics for *Clostridium difficile* associated diarrhea: focus on *Lactobacillus rhamnosus* GG and *Saccharomyces boulardii*. *Annals of Pharmacotherapy* **41** 1284–1287
- Songer JG & Anderson MA** 2006 *Clostridium difficile*: an important pathogen of food animals. *Anaerobe* **12** 1–4
- Sunenshine RH & McDonald LC** 2006 *Clostridium difficile*-associated disease: new challenges from an established pathogen. *Cleveland Clinical Journal of Medicine* **73** 187–197
- Toothaker RD & Elmer GW** 1984 Prevention of clindamycin-induced mortality in hamsters by *Saccharomyces boulardii*. *Antimicrobial Agents and Chemotherapy* **26** 552–556
- Trejo FM, Minnaard J, Pérez PF & De Antoni GL** 2006 Inhibition of *Clostridium difficile* growth and adhesion to enterocytes by *Bifidobacterium* supernatants. *Anaerobe* **12** 186–193
- Trejo FM, Pérez PF & De Antoni GL** 2010 Co-culture with potentially probiotic microorganisms antagonises virulence factors of *Clostridium difficile* in vitro. *Antonie van Leeuwenhoek* **98** 19–29
- Waters EH, Orr JP, Clark EG & Schaefe CM** 1998 Typhlocolitis caused by *Clostridium difficile* in suckling piglets. *Journal of Veterinary Diagnostic Investigation* **10** 104–108
- Wullt M, Hagslatt ML & Odenholt I** 2003 *Lactobacillus plantarum* 299v for the treatment of recurrent *Clostridium difficile*-associated diarrhoea: a double-blind, placebocontrolled trial. *Scandinavian Journal of Infectious Diseases* **35** 365–367
- Xiao JZ, Takahashi S, Odamaki T, Yaeshima T & Iwatsuki K** 2010 Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. *Bioscience Biotechnology and Biochemistry* **74** 336–342